United States buys up virtually entire global supply of key coronavirus drug remdesivir


The drug helps coronavirus patients recover more quickly and is the manufacturer is charging $2,340 per patient for the treatment

The United States has bought up virtually the whole supply of a drug that could shorten the recovery time of coronavirus patients.

That represents 100 per cent of Gilead’s projected production for July, and 90 per cent for each of the next two months.

Alex Azar, the US health secretary, said: « President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19. To the extent possible, we want to ensure that any American patient who needs remdesivir can get it.

« The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The price tag is slightly below the range of $2,520 to $2,800 suggested last week by US drug pricing research group the Institute for Clinical and Economic Review (ICER).

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of the virus.

After the intravenously administered medicine helped shorten hospital recovery times in a clinical trial, it won emergency use authorisation in the United States and full approval in Japan.

Remdesivir had previously failed as an Ebola treatment and has not shown that it can reduce coronavirus deaths.

We urge you to turn off your ad blocker for The Telegraph website so that you can continue to access our quality content in the future.

SOURCE: https://www.w24news.com

Abonnez-vous gratuitement et soyez le premier à liker et à partager:

Je m’abonne gratuitement pour rester informé!!!

Votre point de vue compte, donnez votre avis

Laisser un commentaire

Téléchargez notre application Android


Please enter your comment!
Please enter your name here